All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How to identify and mitigate neurologic AEs when treating with CAR-T and T-cell engagers?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you identify and mitigate neurologic adverse events (AEs) when treating with chimeric antigen receptor (CAR)-T and T-cell engagers?

In this video, Einsele discusses the identification, management, and prophylaxis of severe neurologic toxicities associated with treatment with CAR-T and T-cell engagers.

 

Share: